Ensitrelvir to Prevent COVID-19 in Households: SCORPIO-PEP Phase III Placebo-Controlled Trial Results

Hayden et al., CROI 2025, SCORPIO-PEP, Mar 2025
Symp. case 68% improvement lower risk ← → higher risk Ensitrelvir  SCORPIO-PEP  PROPHYLAXIS RCT Is prophylaxis with ensitrelvir beneficial for COVID-19? Double-blind RCT 2,041 patients in multiple countries Fewer symptomatic cases with ensitrelvir (p<0.000001) c19early.org Hayden et al., CROI 2025, March 2025 0 0.5 1 1.5 2+ RR
49th treatment shown to reduce risk in July 2023, now with p = 0.015 from 8 studies.
Lower risk for hospitalization, recovery, cases, and viral clearance.
No treatment is 100% effective. Protocols combine treatments.
6,300+ studies for 210+ treatments. c19early.org
Meta Analysis
RCT 2,041 household contacts showing significantly lower symptomatic COVID-19 cases with ensitrelvir post-exposure prophylaxis.
Important missing comments or errors? Let us know.
risk of symptomatic case, 67.6% lower, RR 0.32, p < 0.001, treatment 30 of 1,030 (2.9%), control 91 of 1,011 (9.0%), NNT 16.
Effect extraction follows pre-specified rules prioritizing more serious outcomes. Submit updates
Hayden et al., 9 Mar 2025, Double Blind Randomized Controlled Trial, placebo-controlled, multiple countries, peer-reviewed, 15 authors, SCORPIO-PEP trial.
Please send us corrections, updates, or comments. c19early involves the extraction of 200,000+ datapoints from thousands of papers. Community updates help ensure high accuracy. Treatments and other interventions are complementary. All practical, effective, and safe means should be used based on risk/benefit analysis. No treatment or intervention is 100% available and effective for all current and future variants. We do not provide medical advice. Before taking any medication, consult a qualified physician who can provide personalized advice and details of risks and benefits based on your medical history and situation. IMA and WCH provide treatment protocols.
  or use drag and drop   
Submit    
Post
Share
@CovidAnalysis
FAQ
Public domain CC0 1.0